PTEN and prostate carcinoma: We here show that phospho-specific mAbs measuring activity states of signaling molecules in the core PI3K and MAPK pathways can substitute for PTEN, and identify pPRAS40 and pS6 as novel, lethal outcome-predictive markers for prostate cancer.